Chemical Structure (Keppra 01)
Keppra Injection, Solution, Concentrate
Product Images NDC 50474-002
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Keppra (NDC 50474-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Keppra 02)
This is a chart that shows the percentage of patients using different doses of KEPPRA- 1000 mg/day and 3000 mg/day. The chart also indicates that there were 97 patients in the 1000 mg/day group and 101 patients in the 3000 mg/day group. However, it is not clear what the asterisks (*) represent.*
Figure 2 (Keppra 03)
Figure 3 (Keppra 04)
This data represents the results of a clinical trial where the effectiveness of KEPPRA medication was compared with a placebo. The percentage values 39.4% and 14.4% may refer to the proportion of participants who experienced a certain outcome or improvement from taking the medication. The size of the groups is also given as N=104 for the placebo group and N=180 for the group of participants taking KEPPRA at a dose of 3000 mg/day. However, without additional context or information, it is difficult to provide a more detailed description of the study findings.*
Figure 4 (Keppra 05)
This appears to be incomplete data and does not provide any context to generate a meaningful description. It seems to be part of a table or chart displaying numerical values related to a study involving a placebo group and a group taking Keppra, but without knowing what these percentages represent, it is not possible to generate a description.*
Figure 5 (Keppra 06)
This appears to be a table of percentages for two different groups of patients, one taking a drug called KEPPRA and the other taking a placebo. The KEPPRA group has a percentage of 43.1% while the placebo group has a percentage of 19.6%. The numbers in parentheses after the drug and placebo represent the number of patients in each group.*
Figure 6 (Keppra 07)
This appears to be a table showing percentages of patients for a medication called "KEPPRA" and a placebo group with N=84. The table also shows an entry with 722%, which is likely a data entry error. There is no further context or explanation provided.*
Principal Display Panel (5 mL Vial Carton)
This is a description of Tevetiracetam injection, also known as Proprnis. It contains 500 mg of the medicine in a 5 mL solution, with a concentration of 100 mg/mL. Prior to administration, it should be diluted. The storage temperature is recommended to be at 28C and it should not be exposed to temperatures above 40C. The supplier of this medication is not mentioned in the text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
